Skip to content

Harrow HROW Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$8.58B+1.6%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.83B+49.6%
Opko Health logo
Opko HealthOPK
$3.57B+2.5%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$295M+34.1%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$782.84M+7.6%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$1.42B+16.8%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.8B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's additional paid-in capital?
Harrow (HROW) reported additional paid-in capital of $212.8M in Q1 2026.
How has Harrow's additional paid-in capital changed year-over-year?
Harrow's additional paid-in capital decreased by 5.7% year-over-year, from $225.58M to $212.8M.
What is the long-term trend for Harrow's additional paid-in capital?
Over 5 years (2020 to 2025), Harrow's additional paid-in capital has grown at a 14.8% compound annual growth rate (CAGR), from $104.56M to $208.93M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.